Ultimovacs ASA: First Quarter 2021 Result Presentation
b'Ultimovacs ASA ("Ultimovacs", ticker ULTI), a pharmaceutical company developing novel immunotherapies against cancer, announces its first quarter 2021 results today.
- b'Ultimovacs ASA ("Ultimovacs", ticker ULTI), a pharmaceutical company developing novel immunotherapies against cancer, announces its first quarter 2021 results today.
- A presentation by the Company\'s management team will take place today on a webcast at 09:00 CEST.
- (post period event).\nTotal operating expenses amounted to MNOK 31.2 in Q1-21.\nCash flow from operations was MNOK -29.5 in Q1-21.
- Total cash and cash equivalents amounted to MNOK 409.3 as per 31 March 2021.\nFor further information, please visit www.ultimovacs.com or contact:\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210510005617/en/\n'